Drug reference

nvx-cov2373

nanoparticle vaccine · vaccine

nanoparticle vaccinevaccine

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

—

not curated

Mechanism

NVX-CoV2373 contains nanoparticles coated with synthetic spike proteins. Once injected with adjuvant, these particles are taken up by antigen-presenting cells (APCs) which present the spike proteins, resulting in an immune response.

Indications

prevention of severe or fatal COVID-19

Dosing

Adult: injected in two doses 21 days apart

Related guidelines

Stroke and TIA — secondary prevention

AHA · Neurology · 2021

Tobacco-related cancer prevention

ICMR · Oncology · 2021

Cardiovascular disease prevention

ESC · Cardiology · 2021

Primary prevention of cardiovascular disease

AHA · Cardiology · 2019

Infective endocarditis prevention

ADA_DENTAL · Dentistry · 2015

Ask House about nvx-cov2373

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team